In the LC‐SCRUM‐Liquid study,23 which evaluated plasma cell‐free DNA and tissue‐based sequencing concordance for comprehensive oncogenic driver detection in NSCLC, the KRAS mutation detection rate was 12.1%. Here, KRAS is linked to non-small cell lung carcinoma.